摘要
目的:评价舒血宁注射液治疗急性脑梗死的临床疗效和安全性。方法:按照Cochrane系统评价的方法进行文献检索和数据提取,用RevMan 5.1软件对文献数据进行荟萃分析。结果:纳入8项随机对照临床试验,涉及726例病人。荟萃分析结果显示:治疗结束时,舒血宁治疗组病人的神经功能缺损改善情况优于对照组,加权均数差(95%CI)分别为-5.69(-6.59,-4.80)和-3.54(-5.86,-1.22)。治疗组的临床有效率优于对照组,风险比(95%CI)分别为1.15(1.07,1.25)和1.15(1.03,1.28)。两组病人的药品不良反应(ADRs)发生率无统计学差异。结论:舒血宁注射液可有效改善急性脑梗死病人的神经功能缺损,提高治疗有效率,不增加ADRs的风险,可用于急性脑梗死治疗中保护病人脑部神经。
Objective： To evaluate the clinical efficacy and safety of Shuxuening injection in treatment of patients with acute cerehral infarction（ACI）. Methods： Literature retrieval and data extraction were made with the method of Coehrane systematic review. Meta analysis was performed by using RevMan 5.1 software, Results： Eight randomized control clinical trials involving 726 patients were included in this study. Meta analysis indicated that improvement of neurological function in the Shuxuening injection group was superior to that of the control group=weighted mean difference（WMD） --5.69,95 ~CI （--6. 59,--4.80） vs WMD----3.54,95 Y/0CI （ 5.86,--1. g2） ,respectively. Clinical effective rate for the treatment group was significantly high er than that of lhe control group：risk ratio（RR） = 1.15,95~/0CI （1.07,1.25） vs RR-- 1.15,95~CI （1.03,1.28） ,respectively. There were no statistical differences in incidence of adverse drug reactions （ADRs） between the two groups. Conelusion Shuxuening injection can effectively improve the neurological function and increase treatment efficiency of ACI patients without higher risks of ADRs. It can be used to protect neurological function of patients with ACI.
出处
《药学服务与研究》
CAS
CSCD
2012年第5期354-357,共4页
Pharmaceutical Care and Research
关键词
舒血宁注射液
脑梗死
急性
荟萃分析
Shuxuening injeetion
cerebral infarction, acute ~ meta analysis
